To help inform healthcare treatment practices and funding decisions, an economic evaluation was conducted to compare the two leading gonadotrophins used for IVF in Belgium. Based on the results of a recently published meta-analysis, a simulated decision tree model was constructed with four states: (i) fresh cycle, (ii) cryopreserved cycle, (iii) live birth and (iv) treatment withdrawal. Gonadotrophin costs were based on highly purifi ed human menopausal gonadotrophin (HP-HMG; Menopur) and recombinant FSH (rFSH) alpha (Gonal-F). After one fresh and one cryopreserved cycle the average treatment cost with HP-HMG was lower than with rFSH (HP-HMG €3635; rFSH €4103). The average cost saving per person started on HP-HMG when compared with rFSH was €468. Additionally, the average costs per live birth of HP-HMG and rFSH were found to be signifi cantly diff erent: HP-HMG €9996; rFSH €13,009 (P < 0.0001). HP-HMG remained cost-saving even after key parameters in the model were varied in the probabilistic sensitivity analysis. Treatment with HP-HMG was found to be the dominant treatment strategy in IVF because of improved live birth rates and lower costs. Within a fi xed healthcare budget, the cost-savings achieved using HP-HMG would allow for the delivery of additional IVF cycles.
Introduction
Over the past decade demand for assisted reproductive technologies (ART) has increased internationally. 1, 2 Despite increasing medical need and demand for fertility treatments many national and private insurers frequently ration access to treatment or do not provide reimbursement. 3, 4 The decision to ration access is often driven by a desire to cut rising healthcare expenditure attributed to an ageing population.
The consequences of rationing and limiting public access to services ca n be devastating for couples that must pay out of pocket for services. Because of the relationship between ability to pay and acces s to ART, it is clear that many couples must go without treatment. 6, 7, 8 Over reliance on a user pays system has lead to considerable debate regarding whether or not access to state funded IVF is an extension of the basic human right to family formation defi ned by the Unite d Nations. 9, 10, 11 While many countries have sought to limit ART expenditure in recent years, Belgium is an exception to the norm where funding has been increased to allow for up to six IVF cycles per couple. 12 In c re ased funding in Belgium was partially driven by applying rational health economics arguments to inform ART policy. In a study which assessed the costs associated with multiple pregnancies resu lting from multiple embryo transfer, it was concluded that state funded IVF in which the number of embryos transferred is restricted to one would be cost saving because of a resulting reductions in the number of multiple births and resulting premature births and its short and long term cost consequences. 13, 14 Despite increased ART funding this does not suggest Belgium health authorities are frivolous with resources as they continuously strive for improved effi ciency in the delivery of IVF. In 2003 Be lgium established a fi xed IVF payment per cycle which covers oocyte retrieval, fertilisation, laboratory related activities, staff costs, as well as cryopreservation which includes freezing, storing and thawing. As an extension of this reform policy makers now seek to establish a fi x reimbursement payment system for all gonadotrophins used for ovarian stimulation. To achieve this requires accurate dosing data on which to derive a weighted price amongst the various gonadotrophin presentations. The establishment of a gonadotrophin forfait would be an eff ective policy if all gonadotrophin products were equivalent. However, if the products are not equivalent, a fl at reimbursement rate could decrease effi ciency if the forfait is set above the price of the more cost-eff ective product. This stresses the need to base such important policy decisions on costs and live birth rates and not costs alone.
To inform future policy decision we have performed an economic evaluation taking into consideration not only costs, but also diff erences in live birth rates achieved between the various gonadotrophin presentations. The clinical data on which the analysis is based is from a recent systematic review and meta-analysis of seven randomised gonadotrophins releasing hormone long protocol studies. 15 The economic evaluation was designed to evaluate the leading gonadotrophins MENOPUR (HP-hMG) and GONAL-F (recombinant FSH alpha) in Belgium with market shares of 40.0% and 37.8%, respectively. 16 Furthermore, to refl ect 'real world ' practices we have incorporated cryopreserved live birth rates from registry data in Belgium with the Coomarasamy live birth data. By synthesizing the live bi rth rates from two sources of evidence this represents real world treatment practices of patients failing 1 fresh cycle and advancing to a cryopreserved cycle. However, it should be acknowledged that modelling exercises of this nature are an approximation of well prospective randomised trials. None the less, it is envisaged that the analysis described here will allow payers to understand the relationship between cost and outcomes by comparing the 'costs per live birth' for the leading gonadotrophins rather than focusing solely on drug acquisition costs.
Materials and methods

Clinical evidence
The live birth data on which the economic evaluation is based was derived from two sources. Live birth rate data was taken from a recently reported meta-analysis of seven studies using long-agonist protocols which showed an 18% relative increase in live births with hMG compared to rFSH (RR= 1.18, 95% CI: 1.02 to 1.38, p=0.03). 15 The inclusion criteria for the seven studies were broadly similar, with some notable diff erences regarding excludable age and maximum body-mass index. The ovarian hyperstimulation syndrome (OHS S) rate for HP-hMG and rFSH applied in the model were 0.019 and 0.01, respectively, and as previously reported these diff erences were nonsignifi cant. 17 The miscarriage rates were defi ned as the remainder of people reporting clinical pregnancy that did not progress to live birth. Additionally, to refl ect Belgian success rates, data on cryoprese rved embryos was extracted from the Belgian register for assisted procreation (BELRAP) to model availability and success rates using frozen embryos in Belgium. 18 
Model design Model design
To assess the comparative cost-eff ectiveness of HP-hMG and rFSH we developed a simulated decision tree with the following health events: 19 (1) start fresh treatment (2) cryopreser ved cycle (3) live birth and (4) treatment withdrawal, in which all patients started in fresh treatment. The model was constructed using Treeage Pro He althcare 2007 (Release 1.0) using a Markov structure, however the model is not Markovian as it is time independent. The model explored costs and outcomes of two cycles which included an opportunity for using cryopreserved embryos where available. The scenarios assessed were: Cycle-1, one fresh cycle for all patients; Cylce-2, a second consecutive fresh cycle or one frozen cycle based on the probability of cryopreserved embryos being available. 20 Based on previously reported withdraw rates from Belgium couples could withdraw from treatment at various stages as follows: (1) cancellation of fresh cycle; (2) unsuccessful fertilisation; (3) unsuccessful embryo implantation; or (4) miscarriage following diagnosis of a clinical pregnancy. 21 Couples continuing treatment were allocated to fresh or frozen cycles depending on the proportion of cycles resulting in frozen embryos reported in BELRAP and confi rmed using a large random ised clinical trial dataset. 22 Couples without frozen embryos proceeded to a second fresh cycle. The model structure is shown in Figure 1 .
We consciously chose not to extrapolate the model beyond one fresh and a second fresh or frozen cycle, because there is insuffi cient randomised live birth rate data for conducting consecutive fresh cycles. Previous economic evaluations which explore consecutive fresh cycles tend to support conclusions observed in the fi rst cycle, because the same success probabilities for both treatments are applied in the consecutive cycles. Hence, treatment benefi ts in consecutive cycles repeat the conclusions observed in the fi rst cycle and consequently adding additional fresh cycles does not provide additional information on which to diff erentiate treatments. 17, 23 Cost input data Cost input data The perspective of the economic evaluation was the Belgium health service, Rijksinstituut voor ziekte-en invaliditeitsverzekering (RIZIV); therefore costs paid by th e couples and lost productivity for time off work were not incorporated into the analysis. Cost data was obtained from a variety of sources including published references, the Genk Institute for Fertility Technology and expert opinion. All costs were adjusted for infl ation to 2007.
No discounting was applied due to the short time horizon employed in the model.
Similar to previous economic studies we only considered those costs directly attributed to the delivery of IVF. 24 Consequently only costs attributed to the administration of IVF and treatment related adverse events have been included in the cost calculations. Furthermore, costs attributed to ongoi ng pregnancies and deliveries were not included in the evaluation because this would inappropriately accrue additional costs to the product with higher live birth rates. Furthermore, we have not assigned costs to treatment withdrawals which may accrue additional costs for counseling services or adoption costs to the least eff ective product.
Pharmaceutical costs
The economic evaluation compares the two leading gonadotrophins in Belgium: highly-purifi ed hMG (MENOPUR, Ferring Pharmaceuticals, St Prex, Switzerland) and recombinant FSH follitropin alpha (GONAL-F, MerckSerono, Geneva, Switzerland). Because of reported diff erences in dosing for rFSH alpha between clinical trials and clinical practice, we considered two dosing scenarios for rFSH in the economic evaluation to refl ect its use in clinical practice. The 'high dose' scenario was based on the weighted mean dose per fresh cycle for HP-hMG and rFSH derived from the studies reported by Coomarasamy as follows: HP-hMG 2,491 IU; rFSH 2,434 IU ( Table 1 ). The 'low dose' rFSH scenario is based on doses obtained from Genk Institute for Fertility Technology in Belgium and shown in Table 1 . Gonadotrophin costs were only applied during the fresh cycles. Costing of gonadotrophins was based on the number of packs required to fulfi ll per cycle dose requirements in each scenario ( Table 1 ). The costs of GnRH agonists for pituitary down regulation and one prescription of Progesterone for luteal support have been included in the model.
Health Service Costs
The major health service cost is attributed to the IVF forfait which covers oocyte retrieval, laboratory procedures, embryo transfer, as well as freezing, storing and thawing of embryos. Doctor consultations are not covered within the forfait payment; therefore we have assumed an average of three clinical consultations during the stimulation period. Nursing consultations Note: There was no diff erence in the amount of HP-hMG used in the low and high dose scenarios. This is a ributed to the observation that the weighted mean dose derived from the trials included in the Coomarasamy meta-analysis and the median dose from Genk University were very similar. Consequently in the high and low dose scenarios the dose and costs of HP-hMG do not change.
have been excluded from the analysis because they are not paid for by RIZIV. Similar to previous economic evaluations in IVF the costs attributed to OHSS were applied as a weighted tariff across both treatment options early in the stimulation phase of the cycle based on reported OHSS frequency for both treatment. 25 All cost input variables in the model are summarized in Table 2 .
Model output Model output
The decision model was evaluated in three diff erent ways. Firstly, the model was assessed deterministically (no randomness) which derives a mean value for each treatment based on fi xed probabilities of outcomes and costs emanating from each branch of the decision tree. The model was validated by comparing the live birth output from the deterministic model output with the live birth data from the Coomarasamy meta-analysis. We observed comparable live birth rates within 0.001 live births suggesting the model was an accurate refl ection of the clinical data on which it was based. 
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Secondly, uncertainty in the model was assessed using Monte Carlo fi rstorder microsimulation techniques. First-order simulations are used to model variability in individual outcomes (ie. live birth or no live birth.) as large cohorts are randomly walked through the model. Using a large simulation cohort of 50,000 we are able to generate average estimates of outcomes which should refl ect deterministic model output.
Thirdly, parameter uncertainty was tested in the model using probabilistic sensitivity analysis (PSA). Also referred to as second-order analysis, PSA is commonly used in medical technology appraisals, and is recommended by the Belgium Health Care Knowledge Centre (KCE) because it allows for simultaneous sampling from defi ned distribution for those parameters where there is likely to be uncertaint. 26 , 27 The uncertainty parameters tested in the sensitivity analysis included: dropout rates, frequency of clinic visits in the stimulation cycle, availability of frozen embryos, and live birth rates achieved using HP-hMG and rFSH alpha from Coomarasamy et al, and live b ir th rates using cryopreserved embryos. Variation in live birth rates for HP-hMG and rFSH alpha were based on the 95% confi dence intervals for each gonadotrophin derived from Coomarasamy and defi ned in the PSA using a beta distribution. 15 Transition probabilities and distributions applied in the PSA are provided in Table 3 . Variations in dose were not included in the PSA but have been tested using diff erent dosing scenarios as previously described (Table 1) . For both rFSH dose scenarios PSA sampli ng of 20,000 simulations were used. 
Statistical comparisons Statistical comparisons
The outputs from fi rst-order and second-order simulation techniques are not interpreted in the same way; therefore output for each simulation was evaluated diff erently. Confi dence intervals from the Monte Carlo fi rst-order microsimulation output were produced by bootstrapping in order to estimate the sample distribution. 28 Applying this method to IVF microsimulation output which produces either a "1" for live birth or "0" for no birth has been previously described. 28 Simulation output from the PSA was normally distributed and was testing using unpaired t-tests. 29 Statistical comparis ons for average cost per person and the average cost-eff ectiveness ratio were performed for both rFSH dosing scenarios. Comparisons were conducted using the software program StatsDirect (version 2.6.6), Cheshire, UK.
Results
The average c ost per person and average cost per live birth for HP-hMG and rFSH using the base case dosing scenario and alternative dosing scenario are presented in Tables 4 and 5 . The average costs per fresh IVF cycle were lower for HP-hMG when compared to the two rFSH dosing regimens: HP-hMG (€2,623); rFSH low dose (€2,921); and rFSH high dose (€2,813). Additionally, after only one fresh IVF cycle the average cost per live birth for HP-hMG, rFSH high dose, and rFSH low dose were €10,288, €13,515, and €13,017, respectively (Table 4) . Based on the average costs-savings per fresh cycle with HP-hMG compared with rFSH high dose, this would suggest that within a fi xed health budget, 1 additional IVF cycle could be delivered after every 8.8 cycles delivered using HP-hMG. The cost-savings achieved when using HP-hMG compared to the rFSH low dose could be used to deliver 1 additional IVF cycle after 13.8 cycles using HP-hMG.
The cumulative live birth data after one fresh cycle and the possibility of one cryopreserved cycle after adjusting for dropouts are shown in Table 5 . After one fresh and one cryopreserved cycle the average treatment costs were lower for HP-hMG when compared with rFSH: HP-hMG (€3,635); rFSH high dose (€4,103); and rFSH low dose (€3,953). The average cost savings per person started on HP-hMG when compared to rFSH high dosing and rFSH low dosing were €468 and €318, respectively. €13,020 ‡ (214) (€12,616 -€13,469) † High and low dose scenarios are based on dose diff erences for rFSH only. The HP-hMG dose is identical in both scenarios. ‡ Comparisons between HP-hMG and rFSH (high and low dose Gonal-F) were found to be signifi cant using unpaired t-tests (p<0.0001). 
(€12,159 -€12,946) ‡ Comparisons between HP-hMG and rFSH (high and low dose Gonal-F) were found to be signifi cant using unpaired t-tests (p<0.0001).
Second order microsimulation
The probabilistic sensitivity analysis tested uncertainty around critical model parameters as previously described based on the two diff erent rFSH alpha dosing scenarios. A comparison of the average cost per live birth and cumulative cost per live birth from the PSA indicated consistency between the deterministic results and the fi rst-order microsimulation (Tables 4 and 5 ). Small variations in the average cost per live birth and the cumulative cost per live birth from the deterministic analysis and the fi rst-order microsimulation refl ects random variation in the simulation methodology. A comparison of the average cost per live birth after one fresh cycle and the average cumulative cost per live birth (one fresh, one frozen) from the PSA for HP-hMG and high dose rFSH was found to be signifi cantly diff erent (p<0.0001). Similarly, the cost per live birth after one fresh cycle and the average cumulative cost per live birth was found to be lower with HP-hMG in comparison to low dose rFSH and this diff erence was found to be signifi cant (p<0.0001).
Discussion
In this study we report the results of an economic evaluation comparing highly purifi ed hMG with follitropin alpha in Belgium. The analysis indicates that using of HP-hMG compared to rFSH alpha results in lower average costs per fresh cycle, lower average cumulative costs for one fresh and one cryopreserved cycle, and lower average costs per live birth. In contrast to previous economic evaluations of gonadotrophins, we have not presented the incremental cost per baby because average treatment costs with HP-hMG are lower than rFSH and has improved success rates resulting in a negative incremental cost-eff ectiveness ratio which is diffi cult to interpret when live births is the primary outcome of interest (Wechowski et al., 2007) . In health economics terms, treatments which have improved outcomes and lower costs are referred to as being the 'dominant' treatment option. 30 To address parameter uncertainty in the model we utilized widely accepted PSA practices used in economic evaluations and recommended by the Belgium health authorities. 27, 31, 32 Based on the output of 20,000 simulations we found that results from the PSA were consist ent with the fi ndings observed in the deterministic (no random) analysis. It is likely that this approach should provide decision-makers and clinicians confi dence in our re su lts and assist with resource allocation decisions.
Previous studies have reported diff erences in doses in the IVF stimulation phase for diff erent gonadotrophin preparations. 2, 34 We have addressed these potential diff erences by using two diff erent dosing scenarios in the model: (1) high dose rFSH scenario based on a pooled sample of over 1000 people treated with HP-hMG and rFSH alpha based on weighted average mean doses; 15 (2) low dose rFSH scenario based on reported dosing practices from the Genk Institute for Fertility Technology. Results from the economic evaluation indicate that while higher doses for HP-hMG may be required in some settings, the higher costs per IU for rFSH a t appropriate doses still results in a more expensive cost per cycle for rFSH alpha. As a result the possibility of higher relative dose requirements with HP-hMG did not impact the cost-eff ectiveness conclusions.
The quality and reliability of all economic evaluations is always dependent on the clinical data on which the analysis is based. Therefore, for economic evaluations to be interpreted appropriate it is important to (1) clearly defi ning the outcome of interest on which the economic evaluation will be based; and (2) describing the clinical data which best refl ects the actual outcome diff erences between the products being compared. In ART the selection of outcomes is relatively straightforward as the main outcome of interest is live birth which can be considered the ultimate treatment outcome. While it is possible to conduct economic evaluations on any clinical outcome in IVF, for example, ongoing pregnancy rates or process utilities, these outcomes are considered intermediate outcomes and do not necessarily refl ect the desired treatment outcomes for couples undergoing IVF. 35, 36 In our evaluation we have used live birth rates as the fi nal outcome on which to base our economic evaluation.
The second critical question to defi ne in economic evaluations is the clinical data that best refl ects the outcomes. Broadly speaking there are tw o schools of thought regarding clinical data for use in economic models: (1) use of a single randomized controlled study or (2) a systematic review approach which combines all available evidence into a meta-analysis to be used in the economic evaluation.
38,39 For many government health authorities there is a growing preference for the use of meta-analysis in health technology appraisals because it provides more precise treatment eff ectiveness which simultaneously addresses heterogeneity. 39 Additionally, recen t good practice guidelines developed by the International Society for Pharmacoeconomic and Outcomes Research (ISPOR) for economic modeling recommend the need for conducting systematic reviews of the literature when developing economic mo dels. 40 Furthermore, ISPOR guidance also suggests that when a systematic approach is not applied that justifi cation needs to be provided as to why studies cannot be combined.
In line with the above recommendations we have utilized the results from a recently re ported systematic review and meta-analysis on which to conduct our economic evaluation (Coomarasamy et al., 2008) . The authors of this study are aware of an additional meta-analysis recently published comparing hMG and rFSH in which results comparable to Coomarasamy were observed. In the study by Al-Inany et al the live-birth rate was signifi cantly higher with HMG et al the live-birth rate was signifi cantly higher with HMG et al [odds ratio (OR) = 1.20, 95% CI = 1.01-1.42] compared to rFSH. 25 As the live birth rates used in our economic evaluation were lower than those reported by Al-Inany et al, it is likely that the results presented here are conservative with respect to average costs per cycle and average cost per live birth.
Within B elgium a fl at reimbursement fee (forfait) is used to cover the costs of IVF. The forfait covers costs related to lab procedures including the search for oocytes, fertilisation by means of IVF/ICSI, growth of the embryo as well as the morphologic evaluation of the embryo's together with cryopreservation (freezing, storing and thawing) of the embryos. In addition, the possibility of establishing a forfait for pharmaceutical products which would include gonadotrophins has been discussed since 2007. Establishing a forfait for pharmaceutical products which is scientifi cally and fi nancially justifi ed is a logical further step to obtain optimal infertility treatment in Belgium. Such a forfait would be a trustable self regulating mechanism for budget control, guaranteeing freedom of choice and responsible prescribing from clinicians.
In the lead up to establishing the maximum pharmaceutical forfait payment there has been considerable debate regarding gonadotrophin doses on which to base the maximum payment. This is an important point because it invariably has cost and effi ciency implications. If the established dose and consequently forfait is below what is required by the patient then the additional costs could fall onto the patient or perhaps worse be sub-optimally stimulated because insuffi cient dose is made available. Alternatively, if the dose in the forfait is higher than necessary this could lead to an ineffi cient payment system resulting in excess payment for less stimulation. While the results presented here will not resolve the debate it does help focus attention on what is perhaps a more important measure; the average cost per live birth. The average cost per live birth encompasses both costs and live birth rates and highlights that there are effi cacy diff erences between the products which are currently being neglected in the forfait debate. It is envisaged that the results presented here can assist policy-makers and health funding agencies design optimal IVF payment systems which consider both costs and outcome diff erences between HP-hMG and rFSH.
Conclusions
The results from our economic evaluation based on a systematic review of human derived and recombinant gonadotrophins and applied to Belgium cost data indicates that a lower average cost per cycle and average cost per live birth can be achieved using HP-hMG compared with rFSH alpha. The base case results were confi rmed in the probabilistic sensitivity analysis in which live birth rates and cost data were varied suggesting the robustness of our conclusions. It is hoped that these results can be used by physicians, couples and healthcare decision-makers to optimise resource allocation decisions which not only increase live birth rates but also save scare healthcare resources.
